What Makes Amgen (AMGN) a New Buy Stock

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting a 1.2% increase in its Zacks Consensus Estimate for the fiscal year ending December 2025 over the past three months. This upward revision in earnings estimates, considered a strong catalyst for near-term stock price movements, positions Amgen within the top 20% of Zacks-covered stocks and suggests potential for favorable price action.

Analysis

Amgen (AMGN) has received a rating upgrade to a Zacks Rank #2 (Buy), a move predicated on positive revisions to its earnings estimates. Specifically, the Zacks Consensus Estimate for the fiscal year ending December 2025 has increased by 1.2% over the past three months, signaling improved analyst sentiment on the company's near-term earnings potential. This places the stock in the top 20% of companies covered by the rating system, suggesting it may attract momentum-focused investors. However, it is critical to note that the projected earnings per share of $20.85 for fiscal year 2025 is expected to be unchanged compared to the prior year's reported figure. This indicates that while the earnings outlook has modestly improved, analysts are not yet forecasting a return to year-over-year earnings growth for the period, a key consideration for fundamental valuation.

Key Decisions for Investors

• Investors may interpret the upgrade to a Zacks Rank #2 (Buy) and the 1.2% increase in consensus estimates as a positive near-term momentum indicator, potentially signaling favorable price action.
• Given the flat year-over-year EPS growth forecast for 2025, long-term investors should conduct deeper due diligence on Amgen's product pipeline and market catalysts to justify a position beyond short-term sentiment shifts.
• It is prudent to monitor subsequent earnings estimate revisions to see if the positive trend accelerates and translates into an improved year-over-year growth outlook, which would provide a stronger fundamental buy signal.